Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$12.19 - $22.43 $6.02 Million - $11.1 Million
-493,967 Reduced 100.0%
15 $0
Q3 2023

Nov 09, 2023

BUY
$13.28 - $20.3 $69,547 - $106,311
5,237 Added 1.07%
493,982 $8.34 Million
Q2 2023

Aug 09, 2023

SELL
$11.66 - $26.0 $70,379 - $156,936
-6,036 Reduced 1.22%
488,745 $6.71 Million
Q1 2023

May 09, 2023

BUY
$19.47 - $28.49 $294,425 - $430,825
15,122 Added 3.15%
494,781 $11.2 Million
Q4 2022

Feb 10, 2023

SELL
$18.08 - $30.0 $441,224 - $732,120
-24,404 Reduced 4.84%
479,659 $11.3 Million
Q3 2022

Nov 09, 2022

SELL
$22.51 - $34.32 $275,387 - $419,870
-12,234 Reduced 2.37%
504,063 $13.1 Million
Q2 2022

Aug 09, 2022

SELL
$16.0 - $45.99 $1.51 Million - $4.35 Million
-94,525 Reduced 15.48%
516,297 $11.3 Million
Q1 2022

May 09, 2022

BUY
$33.17 - $46.98 $17,580 - $24,899
530 Added 0.09%
610,822 $27.4 Million
Q4 2021

Feb 11, 2022

BUY
$39.06 - $67.58 $7.42 Million - $12.8 Million
189,918 Added 45.18%
610,292 $26.2 Million
Q3 2021

Nov 10, 2021

SELL
$60.13 - $77.6 $143,891 - $185,696
-2,393 Reduced 0.57%
420,374 $28 Million
Q2 2021

Aug 10, 2021

BUY
$50.07 - $76.78 $37,051 - $56,817
740 Added 0.18%
422,767 $31 Million
Q1 2021

May 11, 2021

SELL
$58.92 - $97.33 $1.79 Million - $2.96 Million
-30,364 Reduced 6.71%
422,027 $28.9 Million
Q4 2020

Feb 05, 2021

BUY
$43.6 - $73.05 $15.4 Million - $25.8 Million
352,568 Added 353.19%
452,391 $30.4 Million
Q3 2020

Nov 10, 2020

BUY
$38.47 - $52.03 $500,879 - $677,430
13,020 Added 15.0%
99,823 $5.14 Million
Q2 2020

Aug 06, 2020

BUY
$27.28 - $43.01 $2.37 Million - $3.73 Million
86,803 New
86,803 $3.27 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $739M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Gw&K Investment Management, LLC Portfolio

Follow Gw&K Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gw&K Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gw&K Investment Management, LLC with notifications on news.